1_MC1 ._. Introduction_NN1 
Monepantel_NN1 (_( trade_NN1 name_NN1 Zolvix®_NP1 )_) was_VBDZ launched_VVN ,_, firstly_RR in_II New_NP121 Zealand_NP122 in_II 2009_MC ,_, and_CC then_RT in_II Australia_NP1 and_CC the_AT UK_NP1 in_II 2010_MC by_II Novartis_NP1 Animal_NP1 Health_NP1 ._. It_PPH1 was_VBDZ the_AT first_MD new_JJ drug_NN1 family_NN1 of_IO anthelmintic_NN1 to_TO appear_VVI on_II the_AT livestock_NN healthcare_NN1 market_NN1 for_IF over_RG 25_MC years_NNT2 (_( Kaminsky_NP1 et_RA21 al._RA22 ,_, 2008_MC )_) ._. In_II an_AT1 effort_NN1 to_TO prolong_VVI the_AT useful_JJ life_NN1 of_IO this_DD1 new_JJ compound_NN1 and_CC protect_VVI the_AT efficacy_NN1 of_IO the_AT older_JJR anthelmintic_JJ families_NN2 ,_, monepantel_NN1 has_VHZ been_VBN sold_VVN as_II prescription_NN1 only_JJ medicine_NN1 (_( POM-V_NP1 )_) in_II the_AT UK_NP1 ._. Although_CS efforts_NN2 have_VH0 been_VBN made_VVN to_TO "_" protect_VVI "_" the_AT compound_NN1 ,_, the_AT first_MD cases_NN2 of_IO resistance_NN1 have_VH0 been_VBN reported_VVN only_RR two_MC years_NNT2 after_II its_APPGE launch_NN1 ._. The_AT first_MD case_NN1 of_IO resistance_NN1 was_VBDZ reported_VVN in_II sheep_NN and_CC goats_NN2 in_II New_NP121 Zealand_NP122 (_( Leathwick_NP1 et_RA21 al._RA22 ,_, 2013_MC ;_; Scott_NP1 et_RA21 al._RA22 ,_, 2013_MC )_) and_CC another_DD1 case_NN1 was_VBDZ reported_VVN on_II a_AT1 goat_NN1 farm_NN1 in_II New_NP131 South_NP132 Wales_NP133 ,_, Australia_NP1 (_( https://wormmailinthecloud.wordpress.com/?s=monepantel+resistance_NP ;_; last_MD accessed_VVN 30APR15_FO )_) ._. All_DB reports_NN2 have_VH0 found_VVN that_CST Teladorsagia_NP121 circumcincta_NP122 was_VBDZ one_MC1 of_IO the_AT parasites_NN2 surviving_VVG treatment_NN1 ._. 
An_AT1 understanding_NN1 of_IO the_AT development_NN1 of_IO anthelmintic_JJ resistance_NN1 and_CC evolvement_NN1 of_IO parasites_NN2 in_II the_AT face_NN1 of_IO anthelmintic_JJ pressure_NN1 is_VBZ key_JJ to_II developing_VVG strategies_NN2 to_TO preserve_VVI their_APPGE efficacy_NN1 ._. Previously_RR different_JJ selection_NN1 processes_NN2 for_IF the_AT assessment_NN1 of_IO anthelmintic_JJ resistance_NN1 have_VH0 been_VBN used_VVN :_: (_( a_ZZ1 )_) comparison_NN1 of_IO anthelmintic_JJ resistant_JJ and_CC sensitive_JJ field_NN1 derived_JJ isolates_NN2 (_( Le_NP121 Jambre_NP122 et_RA21 al._RA22 ,_, 1977_MC ;_; Hall_NP1 et_RA21 al._RA22 ,_, 1978_MC ;_; Kelly_NP1 et_RA21 al._RA22 ,_, 1978_MC ;_; Hunt_NP1 et_RA21 al._RA22 ,_, 2008_MC ,_, 2010_MC )_) ;_; (_( b_ZZ1 )_) experimental_JJ selection_NN1 via_II increasing_VVG sub-therapeutic_JJ dosages_NN2 in_RR21 vivo_RR22 (_( Kates_NP1 et_RA21 al._RA22 ,_, 1973_MC ;_; Colglazier_NP1 et_RA21 al._RA22 ,_, 1974a_MC ;_; Egerton_NP1 et_RA21 al._RA22 ,_, 1988_MC ;_; Giordano_NP1 et_RA21 al._RA22 ,_, 1988_MC ;_; Shoop_NP1 et_RA21 al._RA22 ,_, 1990_MC ;_; Rohrer_NP1 et_RA21 al._RA22 ,_, 1994_MC ;_; Ranjan_NP1 et_RA21 al._RA22 ,_, 2002_MC ;_; Coles_NP1 et_RA21 al._RA22 ,_, 2005_MC )_) ;_; (_( c_ZZ1 )_) in_RR21 vitro_RR22 pressurisation_NN1 and_CC selection_NN1 of_IO individuals_NN2 within_II a_AT1 population_NN1 with_IW an_AT1 inherent_JJ insensitivity_NN1 to_II a_AT1 compound_NN1 and_CC use_VV0 them_PPHO2 for_IF in_RR21 vivo_RR22 trials_NN2 (_( Maingi_NP1 et_RA21 al._RA22 ,_, 1990_MC ;_; Kaminsky_NP1 et_RA21 al._RA22 ,_, 2008_MC )_) ;_; (_( d_ZZ1 )_) comparison_NN1 of_IO populations_NN2 pre-_II and_CC post_II in_RR21 vitro_RR22 anthelmintic_JJ exposure_NN1 (_( Laing_NP1 ,_, 2010_MC ;_; De_NP121 Graef_NP122 et_RA21 al._RA22 ,_, 2013_MC )_) ;_; (_( e_ZZ1 )_) introgression_NN1 of_IO resistant_JJ genes_NN2 into_II sensitive_JJ populations_NN2 through_II the_AT process_NN1 of_IO backcrossing_VVG individuals_NN2 (_( Redman_NP1 et_RA21 al._RA22 ,_, 2012_MC )_) ;_; (_( f_ZZ1 )_) comparison_NN1 of_IO clade_NN1 V_ZZ1 free_JJ living_JJ model_NN1 nematode_NN1 systems_NN2 to_TO extrapolate_VVI information_NN1 on_II parasitic_JJ nematodes_NN2 (_( Driscoll_NP1 et_RA21 al._RA22 ,_, 1989_MC ;_; Chehresa_NP1 ,_, 1996_MC )_) ._. 
Phenotypic_JJ variation_NN1 in_II life_NN1 history_NN1 traits_NN2 following_VVG selection_NN1 for_IF benzimidazole_NN1 (_( BZ_NP1 ;_; Hall_NP1 et_RA21 al._RA22 ,_, 1978_MC ,_, 1981_MC ;_; Kelly_NP1 et_RA21 al._RA22 ,_, 1978_MC ;_; Maingi_NP1 et_RA21 al._RA22 ,_, 1990_MC ;_; Leignel_NP1 and_CC Cabaret_NP1 ,_, 2001_MC )_) and_CC ivermectin_NN1 (_( IV_NP1 ;_; Echevarria_NP1 et_RA21 al._RA22 ,_, 1993a_MC ,_, 1993b_MC )_) resistance_NN1 has_VHZ been_VBN examined_VVN previously_RR in_II a_AT1 number_NN1 of_IO parasite_NN1 species_NN ._. Historically_RR ,_, it_PPH1 was_VBDZ believed_VVN that_CST chemotherapy_NN1 that_DD1 impacts_VVZ on_II adult_JJ parasite_NN1 life_NN1 expectancy_NN1 would_VM result_VVI in_II one_MC1 of_IO the_AT two_MC outcomes_NN2 :_: either_RR earlier_JJR development_NN1 to_II sexual_JJ maturity_NN1 of_IO parasites_NN2 in_BCL21 order_BCL22 to_TO propagate_VVI prior_II21 to_II22 treatment_NN1 ,_, or_CC delayed_JJ development_NN1 to_TO avoid_VVI the_AT effects_NN2 of_IO treatment_NN1 (_( Arneberg_NP1 et_RA21 al._RA22 ,_, 1998_MC ;_; Skorping_NP1 and_CC Read_NP1 ,_, 1998_MC )_) ._. The_AT finding_NN1 from_II the_AT aforementioned_JJ selection_NN1 studies_NN2 would_VM suggest_VVI that_CST the_AT impact_NN1 of_IO the_AT development_NN1 of_IO resistance_NN1 on_II phenotypes_NN2 ,_, as_CSA one_PN1 might_VM expect_VVI ,_, is_VBZ not_XX so_RG clear_JJ21 cut_JJ22 ,_, and_CC it_PPH1 is_VBZ influenced_VVN by_II a_AT1 number_NN1 of_IO host_NN1 related_JJ /_/ physiological_JJ (_( e.g._REX age_NN1 ,_, size_NN1 ,_, diet_NN1 ,_, immune_NN1 status_NN1 ,_, presence_NN1 of_IO conspecifics_NN2 and_CC heterospecifics_NN2 )_) and_CC environmental_JJ factors_NN2 (_( Poulin_NP1 ,_, 1996_MC )_) ._. 
The_AT aims_NN2 of_IO this_DD1 study_NN1 were_VBDR :_: firstly_RR ,_, to_TO generate_VVI T._NP121 circumcincta_NP122 isolates_NN2 selected_VVN for_IF monepantel_NN1 resistance_NN1 from_II previously_RR phenotypically_RR characterised_JJ parental_JJ isolates_NN2 to_TO improve_VVI our_APPGE understanding_NN1 of_IO the_AT development_NN1 ,_, dissemination_NN1 and_CC detection_NN1 of_IO MPTL_NP1 resistance_NN1 and_CC secondly_RR ,_, to_TO assess_VVI the_AT extent_NN1 of_IO phenotypic_JJ changes_NN2 that_DD1 occur_VV0 in_II selected_JJ isolates_NN2 compared_VVN to_II parental_JJ isolates_NN2 following_VVG selection_NN1 for_IF resistance_NN1 to_II MPTL_NP1 ._. 
2_MC ._. Materials_NN2 and_CC method_NN1 
2.1_MC Parasite_NN1 isolates_NN2 
Three_MC T._NP121 circumcincta_NP122 (_( designated_VVN MTci2_NP1 ,_, MTci5_NP1 and_CC MTci7_NP1 )_) isolates_NN2 were_VBDR used_VVN to_TO generate_VVI the_AT MPTL_NP1 resistant_JJ isolates_NN2 ,_, as_CSA outlined_VVN in_II section_NN1 2.2_MC (_( Table_NP1 1_MC1 )_) ._. MTci2_NP1 is_VBZ phenotypically_RR sensitive_JJ to_II all_DB broad_JJ spectrum_NN1 anthelmintics_NN2 (_( unpublished_JJ data_NN )_) whilst_CS MTci5_NP1 and_CC MTci7_NP1 are_VBR phenotypically_RR BZ_NP1 ,_, levamisole_NN1 (_( LV_NP1 )_) and_CC IV_NP1 resistant_JJ (_( Sargison_NP1 et_RA21 al._RA22 ,_, 2001_MC ;_; Bartley_NP1 et_RA21 al._RA22 ,_, 2004_MC ,_, 2005_MC )_) ._. MTci7_NP1 also_RR exhibits_VVZ moxidectin_NN1 (_( MX_NP1 )_) resistance_NN1 (_( Sargison_NP1 et_RA21 al._RA22 ,_, 2005_MC ;_; Wilson_NP1 and_CC Sargison_NP1 ,_, 2007_MC )_) ._. The_AT isolates_NN2 were_VBDR passaged_VVN through_II parasite_NN1 naive_JJ lambs_NN2 that_DD1 were_VBDR housed_VVN under_II conditions_NN2 that_DD1 precluded_VVD contamination_NN1 with_IW other_JJ nematode_NN1 species_NN prior_II21 to_II22 use_NN1 ._. During_II the_AT period_NN1 of_IO selection_NN1 ,_, the_AT parental_JJ isolates_NN2 were_VBDR independently_RR passaged_VVN four_MC times_NNT2 ._. 
2.2_MC Monepantel_NN1 resistance_NN1 selection_NN1 process_NN1 
Three_MC MPTL_NP1 resistant_JJ T._NP121 circumcincta_NP122 isolates_NN2 were_VBDR artificially_RR selected_VVN in_RR21 vivo_RR22 from_II phenotypically_RR characterised_JJ isolates_NN2 using_VVG an_AT1 adaptation_NN1 of_IO a_AT1 previously_RR outlined_JJ methodology_NN1 (_( Coles_NP1 et_RA21 al._RA22 ,_, 2005_MC )_) ._. In_RR21 brief_RR22 ,_, lambs_NN2 were_VBDR initially_RR mono-specifically_RR infected_VVN with_IW approximately_RR 20,000_MC infective_JJ larvae_NN2 of_IO MTci2_NP1 ,_, MTci5_NP1 or_CC MTci7_NP1 ._. Due_II21 to_II22 availability_NN1 of_IO stocks_NN2 ,_, the_AT infective_JJ larvae_NN2 used_VVN to_TO initiate_VVI the_AT infections_NN2 were_VBDR 1_MC1 ,_, 4_MC and_CC 11_MC months_NNT2 old_JJ for_IF MTci7_NP1 ,_, MTci2_NP1 and_CC MTci5_NP1 ,_, respectively_RR ._. All_DB subsequent_JJ infections_NN2 were_VBDR less_DAR than_CSN 1_MC1 month_NNT1 old_JJ when_CS administered_VVN ._. All_DB larvae_NN2 were_VBDR assessed_VVN visually_RR to_TO ensure_VVI they_PPHS2 appeared_VVD active_JJ ._. Prior_II21 to_II22 infection_NN1 all_DB larvae_NN2 were_VBDR stored_VVN in_II 100_MC ml_NNU tapwater_NN1 in_II 75_MC cm_NNU21 2_NNU22 suspension_NN1 culture_NN1 flasks_NN2 (_( Startsedt_NP1 Ltd_JJ ,_, Germany_NP1 )_) between_II 4_MC and_CC 8_MC °C_NNU ._. At_II patency_NN1 ,_, lambs_NN2 were_VBDR administered_VVN monepantel_NN1 (_( Zolvix®_NP1 ,_, Novartis_NP1 Animal_NP1 Health_NP1 )_) at_II 0.125_MC mg/kg_NNU bodyweight_NN1 (_( BW_NP1 )_) ,_, 1/20th_MF of_IO the_AT manufacturer_NN1 's_GE recommended_JJ dose_NN1 rate_NN1 ._. The_AT lowest_JJT dose_NN1 used_VVN was_VBDZ selected_VVN because_CS previous_JJ work_NN1 had_VHD demonstrated_VVN that_CST even_RR a_AT1 dose_NN1 of_IO 1.25_MC mg/kg_NNU BW_NP1 had_VHD been_VBN effective_JJ at_II removing_VVG >99_MC %_NNU of_IO T._NP121 circumcincta_NP122 populations_NN2 (_( Kaminsky_NP1 et_RA21 al._RA22 ,_, 2009_MC )_) ._. Eggs_NN2 from_II surviving_JJ worms_NN2 were_VBDR collected_VVN and_CC cultured_VVN to_TO generate_VVI infective_JJ larvae_NN2 ._. Lambs_NN2 with_IW positive_JJ faecal_JJ egg_NN1 counts_NN2 (_( FEC_NP1 )_) were_VBDR re-treated_VVN at_II increasing_JJ dose_NN1 rates_NN2 of_IO MPTL_NP1 (_( e.g._REX 0.25_MC ,_, 0.5_MC ,_, 0.63_MC ,_, 0.83_MC ,_, 1.25_MC ,_, 1.88_MC and_CC 2.5_MC mg/kg_NNU BW_NP1 )_) until_CS egg_NN1 counts_NN2 dropped_VVD ._. At_II this_DD1 point_NN1 ,_, the_AT larvae_NN2 obtained_VVN from_II the_AT highest_JJT dosage_NN1 were_VBDR either_RR used_VVN to_TO re-infect_VVI the_AT donor_NN1 that_DD1 had_VHD been_VBN previously_RR treated_VVN or_CC used_VVN to_TO infect_VVI a_AT1 new_JJ donor_NN1 ._. At_II patency_NN1 ,_, the_AT process_NN1 was_VBDZ repeated_VVN using_VVG increasing_JJ dose_NN1 rates_NN2 until_CS a_AT1 fully_RR resistant_JJ isolate_NN1 ,_, i.e._REX able_JK to_TO survive_VVI a_AT1 full_JJ therapeutic_JJ dose_NN1 rate_NN1 (_( 2.5_MC mg/kg_NNU BW_NP1 )_) ,_, was_VBDZ generated_VVN ._. Further_JJR information_NN1 can_VM be_VBI found_VVN in_II the_AT supplementary_JJ material_NN1 file_NN1 attached_VVN ._. 
2.3_MC Monepantel_NP1 efficacy_NN1 trial_NN1 design_NN1 
The_AT monepantel_NN1 efficacy_NN1 trial_NN1 overall_RR included_VVD 10_MC groups_NN2 including_II parent_NN1 (_( without_IW anthelmintic_JJ treatment_NN1 )_) and_CC selected_JJ (_( with_IW and_CC without_IW monepantel_NN1 administration_NN1 on_II day_NNT1 28_MC ,_, i.e._REX -CON_NP1 and_CC -MPTL_NP1 )_) isolates_NN2 ._. Five_MC lambs_NN2 were_VBDR randomly_RR allocated_VVN to_II each_DD1 of_IO the_AT 10_MC groups_NN2 :_: MTci2_NP1 ,_, MTci5_NP1 ,_, MTci7_NP1 ,_, MTci7-MPTL_NP1 ,_, MTci2-11-CON_NP1 ,_, MTci5-13-CON_NP1 ,_, MTci7-12-CON_NP1 ,_, MTci2-11-MTPL_NP1 ,_, MTci5-13-MTPL_NP1 ,_, MTci7-12-MTPL_NP1 (_( Table_NP1 1_MC1 )_) ._. The_AT group_NN1 MTci7-MPTL_NP1 is_VBZ a_AT1 treatment_NN1 validation_NN1 group_NN1 ,_, included_VVN for_IF those_DD2 infected_VVN with_IW the_AT parental_JJ isolate_NN1 MTci7_NP1 ,_, to_TO confirm_VVI that_CST MPTL_NP1 was_VBDZ effective_JJ at_II removing_VVG adult_JJ populations_NN2 in_II the_AT original_JJ parental_JJ isolate_NN1 ._. On_II day_NNT1 0_MC ,_, Suffolk_NP1 greyface_JJ wormfree_JJ crossbred_JJ lambs_NN2 of_IO 5_MC to_II 9_MC months_NNT2 were_VBDR challenged_VVN per_II21 os_II22 with_IW 7000_MC infective_JJ larvae_NN2 from_II one_MC1 of_IO the_AT three_MC parental_JJ isolates_NN2 (_( MTci2_NP1 ,_, MTci5_NP1 or_CC MTci7_NP1 )_) or_CC three_MC monepantel_NN1 selected_JJ isolates_NN2 (_( MTci2-11_NP1 ,_, MTci5-13_NP1 or_CC MTci7-12_NP1 )_) according_II21 to_II22 the_AT constituent_NN1 of_IO group_NN1 ._. Faecal_JJ egg_NN1 counts_NN2 were_VBDR conducted_VVN on_II the_AT lambs_NN2 prior_II21 to_II22 the_AT start_NN1 of_IO the_AT trial_NN1 to_TO confirm_VVI their_APPGE worm-free_JJ status_NN1 ,_, and_CC on_II the_AT day_NNT1 of_IO treatment_NN1 (_( day_NNT1 28_MC )_) to_TO allow_VVI the_AT formation_NN1 of_IO groups_NN2 within_II which_DDQ all_DB lambs_NN2 have_VH0 similar_JJ egg_NN1 counts_NN2 ._. Further_JJR FECs_NP2 were_VBDR conducted_VVN throughout_II the_AT trial_NN1 to_TO assess_VVI time_NNT1 to_II patency_NN1 and_CC magnitude_NN1 of_IO egg_NN1 output_NN1 (_( details_NN2 in_II section_NN1 2.3.1_MC )_) ._. On_II day_NNT1 28_MC post-infection_RR ,_, the_AT lambs_NN2 were_VBDR weighed_VVN and_CC dosed_VVN orally_RR by_II syringe_NN1 at_II the_AT manufacturer_NN1 's_GE recommended_JJ dose_NN1 rate_NN1 with_IW either_RR Zolvix®_NP1 (_( 2.5_MC mg/kg_NNU BW_NP1 ;_; -MPTL_NP1 )_) or_CC left_VVN untreated_JJ to_TO act_VVI as_II controls_NN2 (_( -CON_NP1 )_) ._. All_DB anthelmintic_JJ administrations_NN2 were_VBDR rounded_VVN up_RP to_II the_AT nearest_JJT 0.2_MC ml_NNU (_( dosage_NN1 range_NN1 2.5–2.7_MCMC mg/kg_NNU BW_NP1 )_) ._. All_DB of_IO the_AT animals_NN2 were_VBDR necropsied_VVN seven_MC days_NNT2 post-treatment_RR ;_; the_AT methods_NN2 used_VVN to_TO euthanase_VVI the_AT animals_NN2 ,_, remove_VVI and_CC process_VVI their_APPGE organs_NN2 for_IF worm_NN1 burden_NN1 recovery_NN1 were_VBDR as_CSA described_VVN by_II Patterson_NP1 et_RA21 al._RA22 (_( 1996_MC )_) ._. The_AT total_JJ worm_NN1 burdens_NN2 were_VBDR estimated_VVN from_II 2_MC %_NNU sub-samples_NN2 of_IO the_AT abomasal_JJ washings_NN2 and_CC saline_JJ digests_NN2 ._. Recovered_JJ worms_NN2 were_VBDR sexed_VVN and_CC staged_VVN (_( MAFF_NP1 ,_, 1986_MC )_) ._. Due_II21 to_II22 animal_NN1 ,_, material_NN1 and_CC time_NNT1 constraints_NN2 the_AT above_JJ trials_NN2 were_VBDR conducted_VVN at_II two_MC separate_JJ time_NNT1 points_NN2 ._. The_AT controlled_JJ efficacy_NN1 test_NN1 (_( CET_NP1 )_) using_VVG MTci7_NP1 and_CC its_APPGE selected_JJ isolate_NN1 (_( MTci7-12_NP1 )_) was_VBDZ investigated_VVN in_II one_MC1 trial_NN1 whilst_CS MTci2_NP1 ,_, MTci5_NP1 ,_, MTci2-11_NP1 and_CC MTci5-13_NP1 were_VBDR investigated_VVN in_II a_AT1 second_MD trial_NN1 ._. All_DB experimental_JJ procedures_NN2 described_VVN here_RL were_VBDR approved_VVN by_II the_AT Moredun_NP1 Research_NP1 Institute_NP1 Experiments_NP2 and_CC Ethics_NP Committee_NP1 and_CC were_VBDR conducted_VVN under_II the_AT legislation_NN1 of_IO a_AT1 UK_NP1 Home_NP1 Office_NP1 License_NP1 (_( reference_NN1 PPL_NP1 60/03899_MC )_) in_II31 accordance_II32 with_II33 the_AT Animals_NP2 (_( Scientific_JJ Procedures_NP2 )_) Act_NP1 of_IO 1986_MC ._. 
Table_NP1 1_MC1 Teladorsagia_NP121 circumcincta_NP122 isolate_NN1 designations_NN2 pre-_II (_( parent_NN1 )_) and_CC post-selection_RR for_IF monepantel_NN1 resistance_NN1 ._. 
2.3.1_MC Faecal_JJ egg_NN1 count_NN1 
Faecal_JJ samples_NN2 were_VBDR taken_VVN per_II21 rectum_NN1 from_II each_DD1 lamb_NN1 prior_II21 to_II22 infection_NN1 to_TO confirm_VVI that_CST they_PPHS2 were_VBDR negative_JJ for_IF nematode_NN1 eggs_NN2 :_: from_II day_NNT1 8_MC post_II infection_NN1 (_( PI_NP1 )_) egg_NN1 counts_NN2 ,_, eggs_NN2 per_II gram_NNU1 (_( EPG_NP1 )_) ,_, were_VBDR performed_VVN three_MC times_NNT2 a_AT1 week_NNT1 to_TO assess_VVI pre-patency_NN1 of_IO the_AT isolates_NN2 ,_, on_II day_NNT1 27_MC PI_RR prior_II21 to_II22 the_AT anthelmintic_JJ treatment_NN1 (_( day_NNT1 28_MC )_) ,_, and_CC then_RT daily_RR until_CS necropsy_NN1 seven_MC days_NNT2 later_RRR ._. Faecal_JJ egg_NN1 counts_NN2 were_VBDR conducted_VVN throughout_II the_AT trials_NN2 using_VVG a_AT1 modification_NN1 of_IO a_AT1 salt_NN1 flotation_NN1 method_NN1 with_IW a_AT1 sensitivity_NN1 of_IO up_RG21 to_RG22 one_MC1 egg_NN1 per_II gram_NNU1 (_( Christie_NP1 and_CC Jackson_NP1 ,_, 1982_MC )_) ,_, allowing_VVG the_AT evaluation_NN1 of_IO the_AT effectiveness_NN1 of_IO the_AT anthelmintic_JJ on_II faecal_JJ egg_NN1 count_NN1 reduction_NN1 ._. 
2.3.2_MC Eggs_NN2 in_II utero_NN1 and_CC worm_NN1 body_NN1 lengths_NN2 
Twenty_MC individual_JJ adult_JJ worms_NN2 (_( 20_MC male_JJ and_CC 20_MC female_JJ worms_NN2 where_RRQ available_JJ )_) were_VBDR randomly_RR selected_VVN from_II each_DD1 lamb_NN1 within_II a_AT1 group_NN1 ,_, mounted_VVN in_II a_AT1 drop_NN1 of_IO lactophenol_NN1 (_( GCC_NP1 Diagnostics_NP1 )_) on_II a_AT1 microscope_NN1 slide_NN1 and_CC assessed_VVN for_IF fecundity_NN1 ._. The_AT numbers_NN2 of_IO eggs_NN2 in_II utero_NN1 in_II female_JJ worms_NN2 were_VBDR enumerated_VVN at_II magnification_NN1 (_( ×40_FO )_) on_II a_AT1 compound_NN1 microscope_NN1 ._. Images_NN2 were_VBDR captured_VVN (_( Nikon_NP121 D70_NP122 )_) of_IO each_DD1 individual_NN1 for_IF length_NN1 determination_NN1 ;_; where_CS multiple_JJ images_NN2 were_VBDR captured_VVN ,_, the_AT images_NN2 were_VBDR compiled_VVN to_TO form_VVI a_AT1 single_JJ composite_JJ image_NN1 using_VVG an_AT1 image_NN1 editing_NN1 program_NN1 (_( Adobe_NP1 Photoshop_NP1 Elements_NP2 4.0_MC )_) ._. Worm_NN1 lengths_NN2 were_VBDR estimated_VVN using_VVG image_NN1 processing_NN1 software_NN1 (_( ImageJ_NP121 1.46r_NP122 )_) ._. 
2.4_MC Statistical_JJ analysis_NN1 
The_AT main_JJ effects_NN2 to_TO be_VBI investigated_VVN were_VBDR :_: comparisons_NN2 between_II groups_NN2 corresponding_VVG to_II the_AT parental_JJ isolates_NN2 (_( MTci2_NP1 ,_, MTci5_NP1 ,_, MTci7_NP1 )_) ,_, comparisons_NN2 between_II groups_NN2 corresponding_VVG to_II the_AT parent_NN1 and_CC selected_JJ isolates_NN2 (_( versus_II MTci2-11-CON_NP1 ,_, MTci5-13-CON_NP1 ,_, MTci7-12-CON_NP1 )_) ,_, and_CC finally_RR ,_, comparisons_NN2 between_II groups_NN2 corresponding_VVG to_II the_AT selected_JJ isolates_NN2 without_IW treatment_NN1 (_( -CON_NP1 )_) and_CC with_IW treatment_NN1 (_( -MPTL_NP1 )_) (_( versus_II MTci2-11-MTPL_NP1 ,_, MTci5-13-MTPL_NP1 ,_, MTci7-12-MTPL_NP1 )_) ._. 
2.4.1_MC Parasite_NN1 establishment_NN1 and_CC worm_NN1 burden_NN1 
The_AT data_NN on_II each_DD1 stage_NN1 of_IO worm_NN1 burden_NN1 (_( juvenile_JJ ,_, male_JJ ,_, female_JJ and_CC total_JJ )_) in_II individual_JJ lamb_NN1 were_VBDR investigated_VVN by_II fitting_VVG a_AT1 generalised_JJ linear_JJ mixed_JJ model_NN1 (_( GLMM_NP1 )_) to_II the_AT counts_NN2 using_VVG a_AT1 logarithmic_JJ link_NN1 function_NN1 and_CC assuming_VVG the_AT Poisson_NP1 distribution_NN1 ._. Estimates_NN2 of_IO establishment_NN1 rate_NN1 (_( the_AT proportion_NN1 of_IO juvenile_JJ and_CC adult_JJ worms_NN2 recovered_VVN from_II the_AT initial_JJ challenge_NN1 dose_NN1 i.e._REX 7000_MC )_) and_CC development_NN1 rate_NN1 (_( the_AT proportion_NN1 of_IO adult_JJ worms_NN2 out_II21 of_II22 total_JJ worms_NN2 established_VVN )_) were_VBDR obtained_VVN for_IF each_DD1 group_NN1 by_II fitting_VVG a_AT1 GLMMs_NP2 using_VVG a_AT1 logit_NN1 link_NN1 function_NN1 and_CC assuming_VVG the_AT binomial_JJ distribution_NN1 ._. All_DB models_NN2 included_VVD group_NN1 as_II a_AT1 fixed_JJ effect_NN1 ,_, and_CC lamb_NN1 (_( the_AT level_NN1 of_IO each_DD1 observation_NN1 )_) as_II a_AT1 random_JJ effect_NN1 to_TO allow_VVI for_IF over-dispersion_NN1 ._. 
2.4.2_MC Treatment_NN1 efficacy_NN1 
The_AT percentage_NN1 efficacy_NN1 of_IO the_AT treatment_NN1 for_IF each_DD1 selected_JJ isolate_NN1 was_VBDZ calculated_VVN using_VVG the_AT equation_NN1 :_: (_( 1-(T/C)_FO )_) ×100_FO ,_, where_CS C_NP1 and_CC T_NP1 are_VBR the_AT arithmetic_JJ mean_JJ total_JJ worm_NN1 burdens_NN2 or_CC faecal_JJ egg_NN1 counts_NN2 at_II 35_MC days_NNT2 PI_RR of_IO the_AT control_NN1 (_( -CON_NP1 )_) and_CC treated_JJ (_( -MPTL_NP1 )_) groups_NN2 ,_, respectively_RR (_( Coles_NP1 et_RA21 al._RA22 ,_, 1992_MC )_) ._. According_II21 to_II22 Coles_NP1 et_RA21 al._RA22 (_( 1992_MC )_) ,_, anthelmintic_JJ resistance_NN1 was_VBDZ deemed_VVN to_TO be_VBI present_JJ when_CS the_AT mean_JJ percentage_NN1 efficacy_NN1 at_II reducing_VVG faecal_JJ egg_NN1 output_NN1 or_CC worm_NN1 burden_NN1 was_VBDZ less_DAR than_CSN 95_MC %_NNU ._. 
2.4.3_MC Adult_JJ worm_NN1 body_NN1 length_NN1 
The_AT data_NN on_II length_NN1 of_IO male_JJ and_CC female_JJ worms_NN2 were_VBDR each_DD1 analysed_VVN using_VVG a_AT1 linear_JJ mixed_JJ model_NN1 (_( LMM_NP1 )_) ._. The_AT model_NN1 included_VVD group_NN1 as_II a_AT1 fixed_JJ effect_NN1 and_CC lamb_NN1 as_II a_AT1 random_JJ effect_NN1 ._. 
2.4.4_MC Per_JJ21 capita_JJ22 fecundity_NN1 
The_AT worm_NN1 egg_NN1 counts_NN2 in_II utero_NN1 were_VBDR analysed_VVN using_VVG a_AT1 GLMM_NP1 with_IW a_AT1 logarithmic_JJ link_NN1 function_NN1 and_CC assuming_VVG the_AT Poisson_NP1 distribution_NN1 ._. The_AT model_NN1 incorporated_VVD the_AT group_NN1 as_II a_AT1 fixed_JJ effect_NN1 and_CC lamb_NN1 as_II a_AT1 random_JJ effect_NN1 ,_, and_CC worm_NN1 as_II a_AT1 random_JJ effect_NN1 to_TO allow_VVI for_IF overdispersion_NN1 ._. Two_MC separate_JJ GLMMs_NP2 were_VBDR investigated_VVN ,_, with_IW and_CC without_IW an_AT1 offset_NN1 variable_NN1 of_IO the_AT logarithm_NN1 of_IO the_AT female_JJ worm_NN1 length_NN1 ._. An_AT1 additional_JJ GLMM_NP1 was_VBDZ also_RR fitted_VVN to_TO estimate_VVI the_AT effect_NN1 of_IO logarithm_NN1 of_IO the_AT female_JJ worm_NN1 length_NN1 on_II the_AT egg_NN1 counts_NN2 ._. 
2.4.5_MC Time_NNT1 to_II patency_NN1 
The_AT data_NN on_II time_NNT1 to_II patency_NN1 for_IF each_DD1 animal_NN1 were_VBDR calculated_VVN as_II the_AT time_NNT1 when_CS the_AT faecal_JJ egg_NN1 count_NN1 is_VBZ greater_JJR than_CSN or_CC equal_JJ to_II 25_MC eggs_NN2 per_II gram_NNU1 ._. This_DD1 was_VBDZ analysed_VVN using_VVG a_AT1 linear_JJ model_NN1 (_( LM_NP1 )_) ._. The_AT model_NN1 included_VVD the_AT isolate_NN1 ,_, combining_VVG the_AT two_MC groups_NN2 for_IF each_DD1 selected_JJ isolate_NN1 (_( -CON_NP1 and_CC -MPTL_NP1 )_) ,_, as_II a_AT1 fixed_JJ effect_NN1 ,_, because_CS days_NNT2 to_II patency_NN1 are_VBR before_II the_AT treatment_NN1 day_NNT1 (_( i.e._REX day_NNT1 28_MC )_) ._. 
